DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Pharmacological Target Screening and Drug Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) contains 2,320 bioactive compounds approved by regulatory agencies such as the FDA, EMA, HMA, CFDA, and PMDA, or listed in official pharmacopeias (APExBIO). Each compound is supplied as a 10 mM solution in DMSO, stable for up to 24 months at -80°C. The library enables high-throughput and high-content screening (HTS/HCS) for drug repositioning, pharmacological target identification, and mechanism-of-action studies (Wang et al., 2025). Its diversity of mechanisms, including receptor agonists/antagonists, enzyme inhibitors, and ion channel modulators, supports research in oncology, neurodegeneration, and signaling pathways. The collection includes clinically relevant drugs such as doxorubicin, metformin, and atorvastatin, providing researchers with a translationally relevant platform for discovery.

Biological Rationale

The clinical landscape is dominated by polypharmacy, where patients receive multiple drugs concurrently (Wang et al., 2025). This increases the risk of drug-drug interactions, many of which are mediated by cytochrome P450 enzymes, particularly CYP3A4 and CYP3A5. These enzymes metabolize a significant fraction of marketed drugs, influencing efficacy, toxicity, and required dosing (Wang et al., 2025). Drug libraries composed exclusively of FDA-approved molecules, such as the DiscoveryProbe™ collection, offer a translationally relevant set for investigating mechanisms of action, metabolic liabilities, and therapeutic repurposing. These libraries are especially valuable in high-throughput formats that allow interrogation of hundreds to thousands of compounds in parallel, streamlining the identification of new pharmacological targets relevant to disease states including cancer, neurodegeneration, and inflammatory disorders. The curated nature of the DiscoveryProbe™ library, which includes only compounds with established regulatory approval or pharmacopeial listing, ensures that every constituent has known safety and bioactivity profiles, enabling direct translation of hits to advanced research and clinical stages.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library encompasses a wide array of mechanisms of action:

• Receptor Agonists and Antagonists: Compounds modulating GPCRs, nuclear hormone receptors, and tyrosine kinase receptors.
• Enzyme Inhibitors: Molecules targeting kinases, proteases, and metabolic enzymes, including selective CYP3A4 inhibitors critical for modulating drug metabolism (Wang et al., 2025).
• Ion Channel Modulators: Agents regulating sodium, potassium, calcium, and chloride channels.
• Signal Pathway Regulators: Compounds affecting major signaling cascades such as PI3K/AKT, MAPK/ERK, and NF-κB pathways.

Representative drugs include doxorubicin (topoisomerase II inhibitor), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor). The library is pre-dissolved at 10 mM in DMSO, ensuring precise dosing and compatibility with automated liquid handling systems. These mechanistic classes are directly relevant to both basic research and translational applications in oncology, neurodegenerative diseases, cardiometabolic disorders, and infectious diseases. The inclusion of reference compounds enables benchmarking of novel screening platforms and validation of assay performance.

Evidence & Benchmarks

• Cytochrome P450 (CYP) 3A4 and 3A5 metabolize the majority of clinically used drugs, making selective inhibition a key strategy for managing drug-drug interactions (Wang et al., 2025).
• High-throughput screening (HTS) of FDA-approved libraries has identified selective CYP3A4 inhibitors with distinct chemical scaffolds, supporting rapid lead validation (Wang et al., 2025).
• The DiscoveryProbe™ FDA-approved Drug Library supports robust mechanistic screening for enzyme inhibition, signal transduction modulation, and receptor pharmacology (LabPE, 2023).
• Ready-to-use 10 mM DMSO solutions reduce compound loss and variability, improving assay reproducibility (APExBIO).
• Benchmarking studies demonstrate the utility of this library in identifying repositioning opportunities for oncology and neurodegenerative indications (Houston Biochem, 2023).
• All compounds remain stable for 12 months at -20°C and up to 24 months at -80°C, as verified by APExBIO's internal quality protocols (APExBIO).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is broadly applicable in the following domains:

• Drug Repositioning Screening: Facilitates rapid identification of new indications for existing drugs (see also), extending on prior analyses by focusing on high-content mechanistic elucidation.
• Pharmacological Target Identification: Enables systematic deconvolution of disease-relevant pathways using annotated clinical compounds (contrast with necroptosis-focused review).
• Cancer Research Drug Screening: Provides a rich set for oncology-focused screens, surpassing generic chemical libraries in translational value.
• Neurodegenerative Disease Discovery: Supplies clinically relevant agents for pathway validation and therapeutic hypothesis testing.
• Signal Pathway Regulation: Supports dissecting complex cellular signaling in HTS/HCS formats.

Common Pitfalls or Misconceptions

• This library is not suitable for discovering de novo chemical entities; all compounds have prior regulatory or pharmacopeial status.
• Compounds may have overlapping mechanisms; polypharmacology requires orthogonal validation.
• The library is not optimized for large-molecule (biologic) screening; it contains only small-molecule drugs.
• Some compounds, particularly those with metabolic liabilities (e.g., CYP substrates), may have cell line- or species-specific effects.
• Not all compounds are suitable for in vivo translation without further toxicological assessment, despite prior approval status.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is provided in 96-well microplates, deep well plates, and 2D barcoded screw-top tubes, pre-dissolved at 10 mM in DMSO for automated pipetting. Optimal storage is at -20°C (≤12 months) or -80°C (≤24 months). Shipping is performed on blue ice by default for evaluation samples, with room temperature shipping available on request. Each plate is supplied with a comprehensive compound map and lot-specific certificate of analysis. For successful HTS/HCS integration:

• Thaw plates to room temperature before use to ensure homogeneity.
• Mix well to prevent DMSO stratification; avoid repeated freeze-thaw cycles.
• Use validated liquid handling protocols to achieve final assay concentrations (typically 0.1–10 µM).
• Incorporate positive and negative controls from the same plate for assay normalization.
• Consult the APExBIO product documentation for compound-specific solubility, stability, and handling recommendations (DiscoveryProbe™ FDA-approved Drug Library).

Researchers may compare workflows and troubleshooting insights with those described in this article, which details advanced automation and workflow integration strategies beyond the foundational overview provided here.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO is a validated, regulatory-breadth resource for high-throughput and high-content compound screening. Its mechanistic diversity, stability, and translational relevance empower researchers to accelerate drug repositioning, pharmacological target identification, and advanced signaling pathway interrogation. As demonstrated in recent peer-reviewed studies, selective inhibitor screening and mechanism-of-action elucidation are enabled by such curated libraries (Wang et al., 2025). Ongoing improvements in compound annotation and workflow integration will further expand the utility of the L1021 kit in precision medicine and systems pharmacology research.